Skip to contentR
Revolution Medicines, Inc.
R
RVMDWRevolution Medicines, Inc. Q2 2025 · 10-Q
Revenue—
Net Income-$247.79M-$247.79MN/M vs Q2 2024 EPS Diluted-$1.31-$1.31N/M vs Q2 2024 Operating Income-$264,714,000N/M Operating Cash Flowderived-$221,757,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
Free Cash Flowderived-$229,207,000N/M ended Jun 30, 2025 · filed Aug 6, 2025 · 37 d after period end